CA
NZ
UK
AU
IND
US
• The company's Chief Executive Officer sold $933K of stock.
• Taysha Gene Therapies (NASDAQ: TSHA) has started an underwritten public offering priced at $200.0 million.
• Updated clinical trial results for a therapy targeting Duchenne muscular dystrophy-related heart complications have been reported.
• This includes shares of Common Stock with a par value of $0.001 per share.
• The company is raising approximately $50 million in a private placement financing to support its growth strategy.
• EXoZymes (NASDAQ: EXOZ) receives a $2,028,518 NIH grant to develop rare cannabinoid analogs for drug discovery.
• A decision regarding RP1 for advanced melanoma is expected by August 2, 2026.
• Invitae (NYSE: NVTA) confirms the departure of its chief legal officer as part of a leadership restructuring.
• Facilities receive consistent Medicare payments under current coding.
• A fertility bioscience company filed an 8-K outlining key corporate developments, including an Alabama joint venture.
Please wait processing your request...